Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

271 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluating the Utility and Privacy of Synthetic Breast Cancer Clinical Trial Data Sets.
El Kababji S, Mitsakakis N, Fang X, Beltran-Bless AA, Pond G, Vandermeer L, Radhakrishnan D, Mosquera L, Paterson A, Shepherd L, Chen B, Barlow WE, Gralow J, Savard MF, Clemons M, El Emam K. El Kababji S, et al. Among authors: gralow j. JCO Clin Cancer Inform. 2023 Sep;7:e2300116. doi: 10.1200/CCI.23.00116. JCO Clin Cancer Inform. 2023. PMID: 38011617 Free article.
Optimal Use of Adjuvant Bisphosphonates and Breast Cancer.
Powles TJ, Paterson AHG, Gralow JR. Powles TJ, et al. Among authors: gralow jr. J Clin Oncol. 2017 Aug 10;35(23):2719-2720. doi: 10.1200/JCO.2017.73.6157. Epub 2017 Jun 27. J Clin Oncol. 2017. PMID: 28654362 No abstract available.
Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307).
Kizub DA, Miao J, Schubert MM, Paterson AHG, Clemons M, Dees EC, Ingle JN, Falkson CI, Barlow WE, Hortobagyi GN, Gralow JR. Kizub DA, et al. Among authors: gralow jr. Support Care Cancer. 2021 May;29(5):2509-2517. doi: 10.1007/s00520-020-05748-8. Epub 2020 Sep 15. Support Care Cancer. 2021. PMID: 32929540 Free PMC article. Clinical Trial.
Frequent antibiotic use and second breast cancer events.
Wirtz HS, Buist DS, Gralow JR, Barlow WE, Gray S, Chubak J, Yu O, Bowles EJ, Fujii M, Boudreau DM. Wirtz HS, et al. Among authors: gralow jr. Cancer Epidemiol Biomarkers Prev. 2013 Sep;22(9):1588-99. doi: 10.1158/1055-9965.EPI-13-0454. Epub 2013 Jul 5. Cancer Epidemiol Biomarkers Prev. 2013. PMID: 23833124 Free PMC article.
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.
Gralow JR, Barlow WE, Paterson AHG, M'iao JL, Lew DL, Stopeck AT, Hayes DF, Hershman DL, Schubert MM, Clemons M, Van Poznak CH, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino MJ, Margolis JH, Dakhil SR, Chew HK, Dammann KZ, Abrams JS, Livingston RB, Hortobagyi GN. Gralow JR, et al. J Natl Cancer Inst. 2020 Jul 1;112(7):698-707. doi: 10.1093/jnci/djz215. J Natl Cancer Inst. 2020. PMID: 31693129 Free PMC article. Clinical Trial.
Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.
Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM, Doot RK, Lawton TJ, Barlow WE, Kurland BF, Schubert EK, Mankoff DA. Dunnwald LK, et al. Among authors: gralow jr. J Clin Oncol. 2008 Sep 20;26(27):4449-57. doi: 10.1200/JCO.2007.15.4385. Epub 2008 Jul 14. J Clin Oncol. 2008. PMID: 18626006 Free PMC article.
Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012.
Ellis GK, Barlow WE, Gralow JR, Hortobagyi GN, Russell CA, Royce ME, Perez EA, Lew D, Livingston RB. Ellis GK, et al. J Clin Oncol. 2011 Mar 10;29(8):1014-21. doi: 10.1200/JCO.2009.27.6543. Epub 2011 Jan 10. J Clin Oncol. 2011. PMID: 21220618 Free PMC article. Clinical Trial.
271 results